Thopaz for PALs Evaluation
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Persistent air leak quantification.
- Кому может быть актуально
- Состояния в реестре: Persistent Air Leaks. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- США
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Utility of the Thopaz+ System in Evaluating Persistent Air Leaks
Обзор
Persistent air leaks (PALs) are a common postoperative complication resulting from tears in the visceral pleura or peripheral lung resections. Although highly prevalent with significant consequences, traditional assessment methods lack the capability to objectively quantify air leaks, which further complicates management, results in inconsistent decision making, and prolongs hospital stays. By incorporating the Thopaz+ system, the investigators can introduce a reliable approach to objectively quantify air leaks, potentially improving clinical outcomes. The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the utility of incorporating the Thopaz+ system and its volume quantification ability in evaluating patients with persistent air leaks (PALs) to guide treatment decisions, specifically endobronchial valves (EBVs). In the targeted cohort, the Thopaz+ will be connected to the chest tube and the data collected will be combined with that of serial balloon occlusion testing with a Fogarty balloon to accurately localize the air leak source, and subsequently consider the correct placement of EBVs. The investigators will thereby determine whether this experimental strategy will yield a more accurate and objective assessment of air leaks, facilitating timely interventions and improved patient outcomes.
Подробное описание
The investigators will conduct a prospective controlled clinical trial. The investigators' target demographic includes all adult patients with lung resection and/or non-lung resection-related PAL with ipsilateral chest tubes who were not candidates for surgical intervention or patients who refused the intervention. These patients would undergo a multidisciplinary review by thoracic surgery, interventional pulmonary and the primary care team to consider a bronchoscopic approach with endobronchial valves and possibly bronchial blood patch, which is currently considered standard of care at our institution. During this standard-of-care intervention, quantitative assessment of distal occluded airway pressures/flows in various airways, as well as quantitative assessment of air leak volume will be assessed.
In current medical practice, when EBVs are considered in the context of managing PALs, bronchoscopists may opt to either conduct complete lobar occlusion (sealing of all segments within the target lobe) or segmental occlusion (sealing only selected segments within the target lobe). The decision is usually guided by localizing the source of air leak which is usually done by monitoring the reduction of air leak on the pleural drainage device following serial inflation of a Fogarty Catheter at various locations within the endobronchial tree and monitoring change in air leak visually in the pleural drainage system.
In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.
Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopist will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician.
Continuous monitoring using the Thopaz+ system may continue post-procedure to track changes in air leak volumes and patient recovery, ensuring timely interventions and optimal patient outcomes. This integrated approach aims to provide a more accurate, objective, and efficient method of managing PALs compared to traditional techniques.
Вмешательства
- Диагностический тест Persistent air leak quantification
In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis. Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopic will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to
Первичные конечные точки
- Number of Participants with Successful Intraoperative Quantification of Air Leak Volume Using Thopaz+ Digital Drainage System [Срок оценки: During procedure]
Вторичные конечные точки (10)
- Percentage of patients with identifiable lobar or segmental airways responsible for PAL [Срок оценки: During procedure]
- Maximum decrease in volume of air leak during serial balloon occlusion, as measured by Thopaz+ device [Срок оценки: During procedure]
- Treatment success: decrease of one grade in Cerfolio classification for air leaks or removal of continuous suction from chest drain. [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- Treatment failure: no decrease in the degree of the air leak (Cerfolio classification) and the need for continuous suction for chest drain [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- Length of stay following EBV placement [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- Duration of chest tube following bronchoscopy [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- Change in Air Leak Severity Graded by Cerfolio Classification [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- Change in Quantitative Air Leak Volume Measured by Thopaz+ Digital Drainage System [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- The need for additional non-surgical intervention [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
- The need for additional surgical intervention for PAL such as video-assisted thoracoscopic surgery with mechanical pleurodesis, blebectomy or lobectomy [Срок оценки: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)]
Критерии участия
Критерии включения
- Age ≥ 18 years
- Hospitalized with a persistent air leak (PAL) lasting ≥5 days despite continuous chest tube drainage.
- Undergoing bronchoscopy as part of clinical care for PAL management.
- Able and willing to provide written informed consent
Критерии исключения
- Contraindications to bronchoscopy or EBV placement.
- Pregnancy.
- Inability to tolerate general anesthesia.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
США · 1 центр
- Beth Israel Deaconess Medical Center — Boston
Идентификаторы
NCT: NCT07105436 · 2024P001113